Actimmune Related Published Studies
Well-designed clinical trials related to Actimmune (Interferon Gamma-1B)
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. [2009.07.18]
Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. [2008.05]
Adjuvant interferon gamma in patients with pulmonary atypical Mycobacteriosis: a randomized, double-blind, placebo-controlled study. [2008.02.11]
Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis. 1989. [2008.02]
Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. [2007.03]
A randomized comparative clinical trial of recombinant canine interferon-gamma (KT-100) in atopic dogs using antihistamine as control. [2006.06]
Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. [2005.03]
Effects of interferon-gamma 1b on biomarker expression in patients with idiopathic pulmonary fibrosis. [2004.07.15]
Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. [2004.06.15]
Th1 cytokine pattern (IL-12 and IL-18) in bronchoalveolar lavage fluid (BALF) before and after treatment with interferon gamma-1b (IFN-gamma-1b) or colchicine in patients with idiopathic pulmonary fibrosis (IPF/UIP). [2004.06]
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. [2004.01.08]
Recombinant gamma interferon stimulates signal transduction and gene expression in alveolar macrophages in vitro and in tuberculosis patients. [2003.04]
Interferon-gamma administration does not affect human thyroid hormone metabolism in the post-surgical euthyroid sick syndrome. [2002.04]
Intravesical instillations of interferon gamma in the prophylaxis of high risk superficial bladder cancer--results of a controlled prospective study. [2002]
Double-blind prospective randomized comparison of interferon gamma-1b versus placebo after autologous stem cell transplantation. [2002]
Perioperative treatment with human recombinant interferon-gamma: a randomized double-blind clinical trial. [2001.11]
A phase III study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease. [2001.06.10]
Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma. The Canadian Urologic Oncology Group. [2000.10]
A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters. [2000.04]
A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. [1999.10.21]
Immunochemotherapy with interferon-gamma and multidrug therapy for multibacillary leprosy. [1999.03.15]
Conditioned immune response to interferon-gamma in humans. [1999.02]
Changes in cytokine production of breast cancer patients treated with interferons. [1998.12]
Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. [1998.04.30]
Interferon-gamma in the prevention of severe burn-related infections: a European phase III multicenter trial. The Severe Burns Study Group. [1998.03]
Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group. [1997.10]
Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. [1997.10]
Dose-dependent enhancements by interferon-gamma on functional responses of neutrophils from chronic granulomatous disease patients. [1997.05.01]
A randomized, double-blind study comparing twenty-four-week treatment with recombinant interferon-gamma versus placebo in the treatment of rheumatoid arthritis. [1997.01]
Effect of interferon-gamma, in vitro and in vivo, on mRNA levels of phagocyte oxidase components. [1996.12]
Keloid excision and recurrence prophylaxis via intradermal interferon-gamma injections: a pilot study. [1996.12]
Interferon gamma in trauma-related infections. [1996.10]
Phase II study of interferon-gamma versus interleukin-2 and interferon-alpha 2b in metastatic renal cell carcinoma. [1996.02]
Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis. [1995.04]
Recombinant human interferon-gamma in patients with chronic granulomatous disease--European follow up study. [1995.04]
EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group. [1995.02]
Safety and effectiveness of long-term interferon gamma therapy in patients with chronic granulomatous disease. [1995]
Efficacy trial of topically administered interferon gamma-1 beta gel in comparison to laser treatment in cervical intraepithelial neoplasia. [1995]
Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. [1994.11]
Randomised, controlled study of intratumoral recombinant gamma-interferon treatment in newly diagnosed glioblastoma. [1994.07]
Efficacy of a short course (10 days) of high-dose meglumine antimonate with or without interferon-gamma in treating cutaneous leishmaniasis in Guatemala. [1994.03]
Interferon gamma administration increases monocyte HLA-DR antigen expression but not endogenous interferon production. [1994.02]
Interferons combined with chemotherapy in the treatment of stage III-IV non-small cell lung cancer--a randomised study. [1994]
Immune response induced in small-cell lung cancer by maintenance therapy with interferon gamma. [1993.11.17]
Prospective 5-year followup of recombinant interferon-gamma in rheumatoid arthritis. [1993.11]
Treatment of steroid-dependent asthma with recombinant interferon-gamma. [1993.09]
Immunochemotherapy for visceral leishmaniasis: a controlled pilot trial of antimony versus antimony plus interferon-gamma. [1993.05]
Alpha- and gamma-interferon versus alpha-interferon alone in chronic hepatitis B. A randomized controlled study. [1993.03]
Recombinant interferon gamma therapy for atopic dermatitis. [1993.02]
Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies. [1993.01]
Recombinant human interferon gamma in the treatment of rheumatoid arthritis: double blind placebo controlled study. [1992.09]
Clinical study with recombinant interferon gamma versus interferon alpha-2c in patients with condylomata acuminata. [1992.09]
Treatment with interferon gamma versus interferons alfa and gamma in children with chronic hepatitis B. [1992.08]
Treatment of patients with chronic granulomatous disease with recombinant human interferon-gamma does not improve neutrophil oxidative metabolism, cytochrome b558 content or levels of four anti-microbial proteins. [1992.05]
Increase in neutrophil Fc gamma receptor I expression following interferon gamma treatment in rheumatoid arthritis. [1992.04]
A randomized prospective clinical trial to determine the efficacy of interferon-gamma in severely injured patients. [1992.02]
A prospective randomized comparison of single-agent interferon (IFN)-alpha with the combination of IFN-alpha and low-dose IFN-gamma in chronic myelogenous leukaemia. [1992.02]
Interferon gamma-1b. A review of its pharmacology and therapeutic potential in chronic granulomatous disease. [1992.01]
Enhanced serum levels of soluble HLA class I molecules are induced by treatment with recombinant interferon-gamma (IFN-gamma). [1991.11]
Phase II trial of recombinant DNA gamma-interferon in advanced colorectal cancer: a Southwest Oncology Group study. [1991.10]
A randomised controlled trial of recombinant interferon-gamma in Chinese patients with chronic hepatitis B virus infection. [1991.07]
In vivo interferon-gamma therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae. [1991.04]
A randomized trial comparing a pentavalent antimonial drug and recombinant interferon-gamma in the local treatment of cutaneous leishmaniasis. [1991.03]
High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: a randomized, controlled trial. [1991.02]
Phase II evaluation of recombinant gamma-interferon in patients with advanced pancreatic carcinoma: a Southwest Oncology Group study. [1990.12]
Efficacy of interferons on bowenoid papulosis and other precancerous lesions. [1990.12]
A controlled trial of intralesional recombinant interferon-gamma in the treatment of keloidal scarring. Clinical and histologic findings. [1990.10]
Recombinant gamma-interferon as adjuvant to hepatitis B vaccine in hemodialysis patients. [1990.10]
Treatment of cancer patients with recombinant interferon-gamma induces release of endogenous tumor necrosis factor-alpha. [1990.06]
In vivo biological response to recombinant interferon-gamma during a phase I dose-response trial in patients with metastatic melanoma. [1990.06]
Lack of suppression of IgE production by recombinant interferon gamma: a controlled trial in patients with allergic rhinitis. [1990.05]
Acute effects of single doses of recombinant interferon-gamma on blood cell counts and lymphocyte subsets in patients with advanced renal cell cancer. [1989.08]
Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis. [1989.08]
Antiviral effect of recombinant gamma interferon in chronic hepatitis B virus infection: a pilot study. [1988.02]
Results of a multicenter placebo-controlled double-blind randomized phase III clinical study of treatment of rheumatoid arthritis with recombinant interferon-gamma. [1988]
Well-designed clinical trials possibly related to Actimmune (Interferon Gamma-1B)
Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: results of a Phase I randomized trial. [2009.03.26]
Short-term anti-CD25 monoclonal antibody administration down-regulated CD25 expression without eliminating the neogenetic functional regulatory T cells in kidney transplantation. [2009.03]
A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis. [2009.02.11]
Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. [2009]
Enhanced CBir1-specific innate and adaptive immune responses in Crohn's disease. [2008.12]
A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. [2008.11.15]
Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-up. [2008.10.31]
Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. [2008.09]
A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse. [2008.06.15]
A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine. [2008.06]
Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. [2008.05.23]
Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. [2008.03.04]
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. [2008.01.21]
A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. [2007.12]
[Specific T cell immune response in chronic hepatitis B patients treated with different doses of recombinant hepatitis B vaccine] [2007.12]
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. [2007.11]
Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. [2007.10]
Effects of antifibrotic agents on TGF-beta1, CTGF and IFN-gamma expression in patients with idiopathic pulmonary fibrosis. [2007.08]
Cellular and humoral immune response to a third generation hepatitis B vaccine. [2007.08]
An IL-15 dependent CD8 T cell response to selected HIV epitopes is related to viral control in early-treated HIV-infected subjects. [2007.07]
An ESAT-6:CFP10 DNA vaccine administered in conjunction with Mycobacterium bovis BCG confers protection to cattle challenged with virulent M. bovis. [2007.06.11]
Assessment of the safety, tolerability, and PK/PD properties of two new formulations of subcutaneously administered IFN-beta1a: a double-blind, placebo-controlled comparison with the currently available formulation. [2007.06]
Liver biopsy in cirrhotic patients. [2007.04]
Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. [2007.03.30]
Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. [2007.01.05]
Three-year immune reconstitution in PI-sparing and PI-containing antiretroviral regimens in advanced HIV-1 disease. [2007]
|
